Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alkermes plc ALKS

Healthcare Biotechnology
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products,... see more

Recent & Breaking News (NDAQ:ALKS)

Alkermes to Participate in Upcoming Investor Conferences

PR Newswire November 25, 2024

Alkermes to Participate in Two Upcoming Investor Conferences

PR Newswire November 11, 2024

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

PR Newswire November 7, 2024

Alkermes plc Reports Third Quarter 2024 Financial Results

PR Newswire October 24, 2024

Alkermes to Report Third Quarter Financial Results on October 24, 2024

PR Newswire October 17, 2024

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

PR Newswire September 25, 2024

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

PR Newswire September 23, 2024

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

PR Newswire September 13, 2024

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

PR Newswire August 28, 2024

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

PR Newswire August 22, 2024

Alkermes plc Reports Second Quarter 2024 Financial Results

PR Newswire July 24, 2024

Alkermes to Report Second Quarter Financial Results on July 24, 2024

PR Newswire July 17, 2024

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

PR Newswire June 3, 2024

Alkermes to Participate in Two Upcoming Investor Conferences

PR Newswire May 29, 2024

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

PR Newswire May 28, 2024

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

PR Newswire May 14, 2024

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

PR Newswire May 2, 2024

Alkermes plc Reports First Quarter 2024 Financial Results

PR Newswire May 1, 2024

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

PR Newswire April 24, 2024

Alkermes to Report First Quarter Financial Results on May 1, 2024

PR Newswire April 17, 2024